-continued

tttcggttgc tgtttctgtg 20

<210> SEQ ID NO 5
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic primer

<400> SEQUENCE: 5

atcattggcg tactggagga gcag 24

<210> SEQ ID NO 6
<211> LENGTH: 25
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic primer

<400> SEQUENCE: 6

actatatgga caacgtcaac ccatt 25

<210> SEQ ID NO 7
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic primer

<400> SEQUENCE: 7

accttctgag gcacctggat gt 22

<210> SEQ ID NO 8
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic primer

<400> SEQUENCE: 8

accaccgcaa tgctggcctg c 21

What is claimed is:

1. A method of delivering a viral vector to a subject comprising, administering a composition comprising poly (maleic anhydride-alt-1 octadecene) and the viral vector to the subject.

2. The method of claim **1**, wherein the poly(maleic anhydride-alt-1 octadecene) is substituted with 3-(dimethylamino) propylamine.

3. The method of claim **1**, wherein the composition further comprises a water soluble polymer.

4. The method of claim **1**, wherein the composition further comprises a salt.

5. The method of claim **1**, wherein the composition further comprises a sugar or sugar derivative.

6. The method of claim **5**, wherein the sugar or sugar derivative is selected from group consisting of: glucose, dextrose, fructose, lactose, maltose, xylose, sucrose, com sugar syrup, sorbitol, hexitol, maltilol, xylitol, mannitol, melezitose, raffinose, and combinations thereof.

7. The method of claim **1**, wherein the composition is administered orally to the subject.

8. The method of claim **1**, wherein the composition is in liquid form.

9. The method of claim **8**, wherein the composition is formed by dispersing the viral vector within a solution of poly(maleic anhydride-alt-1 octadecene) at ambient temperatures to form a mixture.

10. The method of claim **1**, wherein the composition is in dry form.

11. The method of claim **10**, wherein the dry form is an amorphous, substantially solid film, which is soluble in an aqueous solution.

12. The method of claim **10**, wherein the composition is produced by a method comprising:

(i) dispersing the viral vector within an aqueous solution comprising the poly(maleic anhydride-alt-1 octadecene); and

(ii) drying the solution.